Increased neopterin concentration in patients with primary arterial hypertension

Artur Cieślewicz; Katarzyna Korzeniowska; Paweł Bogdański; Anna Jabłecka

doi:10.20883/medical.e1

Authors

Artur Cieślewicz Deprtment of Clinical Pharmacology, Poznan University of Medical Sciences, Poland
Katarzyna Korzeniowska Deprtment of Clinical Pharmacology, Poznan University of Medical Sciences, Poland
Paweł Bogdański Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poland
Anna Jabłecka Deprtment of Clinical Pharmacology, Poznan University of Medical Sciences, Poland

DOI:

https://doi.org/10.20883/medical.e1

Keywords:

neopterin, hypertension, inflammation

Abstract

The data on the safety profile of anti-tumor necrosis factor (anti-TNF) therapy in real-life patients cohorts with in flammatory bowel disease (IBD) still are lacking. Neopterin is a pteridine derivative produced from guanosine triphosphate mainly by activated monocytes and macrophages in response to cytokines produced by T-lymphocytes and natural killer cells. Changes in neopterin level reflect the stage of activation of cellular immune system and can be associated with various diseases. Low-grade inflammation is also an important factor in the pathophysiology of hypertension. In presented study we assessed neopterin concentration in 63 patients with primary arterial hypertension compared to 14 control healthy volunteers. Obtained results confirmed increased neopterin level in patients group.

Downloads

Download data is not yet available.

References

Eisenhut M. Neopterin in Diagnosis and Monitoring of Infectious Diseases. Journal of Biomarkers Volume 2013, Article ID 196432, Hindawi Publishing Corporation. http://dx.doi.org/10.1155/2013/196432.

De Rosa S, Cirillo P, Pacileo M, Petrillo G, D'Ascoli GL, Maresca F et al. Neopterin: from forgotten biomarker to leading actor in cardiovascular pathophysiology. Curr Vasc Pharmacol. 2011;9(2):188–199.

Spencer ME, Jain A, Matteini A, Beamer BA, Wang NY, Leng SX, et al. Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat. J Gerontol A Biol Sci Med Sci 2010;65(8):858.

Signorelli SS, Anzaldi M, Fiore V, Candido S, Di Marco R, Mangano K et al. Neopterin: a potential marker in chronic peripheral arterial disease. Mol Med Rep. 2013;7(6):1855–1858.

Avanzas P, Arroyo-Espliguero R, Kaski JC. Role of Neopterin in Cardiovascular Medicine. Rev Esp Cardiol. 2009;62(11):1341–1342.

Visvikis-Siest S, Marteau JB, Samara A, Berrahmoune H, Marie B, Pfister M. Peripheral blood mononuclear cells (PBMCs): a possible model for studying cardiovascular biology systems. Clin Chem Lab Med. 2007;45(9):1154–1168.

Lund-Johansen P. Haemodynamics in early essential hypertension-still an area of controversy. J Hypertens. 1983;1(3):209–213.

Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000;36(3):312–318.

Savoia C, Sada L, Zezza L, Pucci L, Lauri FM, Befani A et al. Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens. 2011;2011:281240. doi: 10.4061/2011/281240. Epub 2011 Sep 11.

Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des. 2006;12(13):1623–1635.

Kozlowska-Murawska J, Obuchowicz A. Clinical usefulness of neopterin. Wiad Lek 2008;LXI:10.

The World Health Report 2002-Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002. Available at http://www.who.int/whr/2002/en.

High Blood Pressure. American Heart Association. American Stroke Association. Statistical Fact Sheet 2013 Update. http://www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ucm_319587.pdf.

Bolívar JJ. Essential Hypertension: An Approach to Its Etiology and Neurogenic Pathophysiology. Int J Hypertens. 2013;2013:547809. doi: 10.1155/2013/547809. Epub 2013 Dec 9.

Schiffrin EL. Immune mechanisms in hypertension and vascular injury. Clin Sci (Lond). 2014;126(4):267–274.

Trott DW, Harrison DG. The immune system in hypertension. Adv Physiol Educ. 2014;38(1):20–24.

Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC. Prognostic value of neopterin levels in treated patients with hypertension and chest pain but without obstructive coronary artery disease. Am J Cardiol. 2004;93(5):627–629.

Asci A, Baydar T, Cetinkaya R, Dolgun A, Sahin G. Evaluation of neopterin levels in patients undergoing hemodialysis. Hemodial Int. 2010;14(2):240–6. doi: 10.1111/j.1542–4758.2010.00439.x. Epub 2010 Mar 10.

Wang H, Cheng Y, Liu Z, Liu Q, Tong H, Wang X et al. Relationship Between Plasma Neopterin and High Sensitivity C-Reactive Protein Levels and Circadian Rhythm of Blood Pressure in Hypertensive Patients with Obstructive Sleep Apnea Syndrome. Am J Hypertens 2012;25(7): 833.

Werner ER, Bichler A, Daxenbichler G, Fuchs D, Fuith LC, Hausen A, Hetzel H, Reibnegger G, Wachter H. Determination of neopterin in serum and urine. Clin Chem. 1987;33(1):62–66.

http://www.neopterin.net/neopterin.